Efficacy of Losartan in Preventing Progression of COPD
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- Change in Percent Emphysema on CT Scan
研究概览
简要总结
Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).
详细描述
Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults with COPD who are either active or former smokers
排除标准
- •Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.
研究组 & 干预措施
Losartan
Losartan 100 mg daily
干预措施: Losartan (Drug)
Placebo
Placebo 1 pill daily
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Percent Emphysema on CT Scan
时间窗: Change between baseline and month 12.
Percent emphysema calculated as percent of CT voxels less than -950 HU measured at TLC. Analysis limited to patients with 5-35% emphysema on CT scan at baseline.
次要结局
- Change in FEV1 (L)(Measured at Baseline and Month 12)
研究者
Robert A. Wise
Professor of Medicine (Pulmonary and Critical Care)
Johns Hopkins University